OrthoPediatrics has launched its RESPONSE Neuromuscular Scoliosis System for treating neuromuscular scoliosis in paediatric patients.
The RESPONSE NM system, which received 510(k) clearance from the US Food and Drug Administration last year, will be introduced on a full scale in the coming months.
OrthoPediatrics noted this surgical system is the 36th system to be launched by the company.
Developed in collaboration with paediatric orthopaedic surgeons, this new system was designed to meet various challenges in treating paediatric patients.
RESPONSE NM builds on the company’s RESPONSE Spine System and consists of a set of implants and instruments with features that streamline insertion. These include options for extreme hyperlordosis and sacral/pelvic fixation.
Shriner’s Hospital for Children, US paediatric orthopaedic surgeon and chief of staff Dr Scott Luhmann was a member of the designing team.
Luhmann said: “Neuromuscular scoliosis patients can present with a wide array of extreme three-dimensional deformities, which can require highly individualised and complicated surgical treatment.
“The addition of the Neuromuscular Scoliosis System to the OrthoPediatrics RESPONSE offering was designed to improve the speed and efficacy of the instrumentation, correction and stabilisation of these complicated deformities, with the aim of optimising outcomes.”
RESPONSE NM can be used along with various systems in OrthoPediatrics’ Scoliosis portfolio which includes the BandLoc Sublaminar banding system and FIREFLY 3D printed pedicle screw guides.
OrthoPediatrics is an exclusive supplier for FIREFLY technology of Mighty Oak Medical in various children’s hospitals in the US.
OrthoPediatrics Scoliosis vice president Jeff Smithey said: “We are excited about the launch of the RESPONSE NM and this first of its kind offering completely focused on implants and instruments for treating neuromuscular scoliosis.
“Our platform of neuromuscular solutions further demonstrates how OrthoPediatrics is uniquely focused on development of products that help paediatric orthopaedic surgeons and their patients around the world.”
The new launch expands the company’s RESPONSE Scoliosis platform for paediatric treatment.